leisure time -WSS

leisure time

author：knowledge 2025-08-12 09:11:38 - browse：453

Element Biosciences exterior -- biotech coverage from STAT — Element Biosciences exterior Element Biosciences

SAN DIEGO — Companies racing to read the genome accurately, quickly, and affordably have hit a snag recently, with several firms reporting that their growth has slowed, stalled, or reversed. Upstart Element Biosciences is hoping it can succeed despite the challenging market conditions.

The San Diego firm launched a $290,000 sequencer, dubbed Aviti, in March 2022 and now has 150 instruments installed in more than 25 countries, according to a sales update Element shared with STAT. The modest growth comes at a time when some other players are struggling. Singular Genomics announced layoffs of 20% of its workforce earlier this year after the lackluster launch of its own sequencer. And Pacific Biosciences recently laid off nearly 200 employees after reporting disappointing first-quarter sales.

Element still has a long way to go in its bid to rival Illumina, a genomics giant that dominates 80% of the sequencing market and has more than 23,000 instruments in use around the world. That includes the NextSeq 2000, a $335,000 sequencer with a similar output to Aviti. Element is betting its blend of accuracy and a more moderate price point can help it carve out a niche of academic and biopharma customers.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Doctors have an ethical obligation to be advocates

focus

WSS

The Readout: Gilead, Bernie Sanders, and other pharma news

'Revelatory' study finds a smoking impact that remains after quitting

What should King Charles tell the public about his cancer?

4 missing after record

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Gilead might be held responsible for not developing a drug

explore

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

New air purifier tech could be key to improving indoor air quality

Readout LOUD podcast: How biotech is using artificial intelligence

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Weekend shootings leave at least 6 dead, 20 others wounded in Chicago

Novavax promises a turnaround & Lilly roils the obesity market

Transgender women dream of pregnancy via uterus transplants

Walensky prepares to leave CDC — and Congress — behind

Gilead might be held responsible for not developing a drug

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How digital tools helped lower hypertension in marginalized patients

focus

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Biogen Alzheimer’s drug launch off to slow start

Woman found dead after suspected bear encounter near Yellowstone, wildlife officials say

Transgender women dream of pregnancy via uterus transplants

New requirements coming in 2024 for Americans traveling to Europe

Novartis develops a rapidly manufactured CAR

focus

focus

hotspot

entertainment